OncoMatch/Clinical Trials/NCT07238686
Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS
Is NCT07238686 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including GPBMC infusion and Venetoclax for myelodysplastic syndromes.
Treatment: Venetoclax · Azacitidine (AZA) or Decitabine (DAC) · GPBMC infusion — This study aims to evaluate the safety and efficacy of a Venetoclax and hypomethylating agent-based regimen combined with infusion of HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cells (GPBMC) in patients with intermediate-risk and higher myelodysplastic syndromes who are ineligible for allogeneic hematopoietic stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage INTERMEDIATE-RISK, HIGH-RISK, VERY HIGH-RISK (IPSS-R)
Risk stratification according to the Revised International Prognostic Scoring System (IPSS-R) must place the patient in the intermediate-, high-, or very high-risk category.
Lab requirements
Kidney function
serum creatinine <= 2 × ULN or CrCl >= 40 mL/min
Liver function
ALT and AST <= 3 × ULN, total bilirubin <= 1.5 × ULN
Cardiac function
LVEF > 50% measured by echocardiogram
Adequate hepatic function including alanine transaminase (ALT) and aspartate aminotransferase (AST )<= 3 × upper limit of normal(ULN), and total bilirubin <= 1.5 × ULN. Adequate renal function including serum creatinine <= 2 × ULN or CrCl>= 40mL/min. LVEF measured by echocardiogram is within the normal range (LVEF > 50%).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify